Prof. Dr. Grimmer is a board-certified psychiatrist and psychotherapist and an Associate Professor working as a Specialist Registrar at the Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany. Prof. Dr. Grimmer is head of the Centre for Cognitive Disorders, specializing in early and differential diagnosis of patients with cognitive impairment. The main focus of Prof. Dr. Grimmer’s research is assessing the usefulness of biomarkers in predicting neurocognitive disorders. He has authored numerous peer-reviewed articles, amongst others, the first studies that assessed the utility of amyloid PET for differential diagnosis of neurodegenerative diseases and tracking Alzheimer’s disease progression. In addition, he has served as a national coordinating investigator and as a principal investigator in more than 70 drug trials, including all monoclonal antibodies against cerebral amyloid load.